What Are Common Antidepressants and How They Work

Most antidepressants prescribed today fall into a handful of drug classes, each defined by how it shifts the balance of chemical messengers in the brain. The most widely used are selective serotonin reuptake inhibitors (SSRIs), followed by serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants like bupropion, and older medications including tricyclics and monoamine oxidase inhibitors. Newer entries, from multimodal serotonin agents to rapid-acting drugs targeting entirely different brain systems, have expanded the toolkit considerably. Understanding what each class does and why some work faster or differently than others can make the whole prescribing process feel less opaque.

SSRIs and Why They Are the Default Starting Point

SSRIs are the most commonly prescribed antidepressants worldwide, and drugs like fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), and paroxetine (Paxil) are household names for a reason. Their mechanism is straightforward in concept: they block the serotonin transporter on the surface of nerve cells, preventing the cell from reabsorbing serotonin after it has been released into the gap between neurons. The result is more serotonin lingering in that gap, available to activate receptors on the neighboring cell.¹ That increased concentration of serotonin at the synapse is considered the primary driver of the antidepressant effect.²

SSRIs became the go-to option because they are relatively targeted. Unlike the older drugs they replaced, they mostly leave other neurotransmitter systems alone, which means fewer side effects for most people. That said, “fewer” is not “none,” and the side effects SSRIs do cause are directly related to serotonin showing up in places beyond the mood-regulating circuits. The gastrointestinal tract, for instance, is packed with serotonin receptors, which is why nausea is one of the most common early complaints. Sexual side effects are another well-known issue, driven by serotonin’s inhibitory effect on sexual desire through specific receptor subtypes.³

SNRIs and the Two-Transmitter Approach

Serotonin-norepinephrine reuptake inhibitors, including venlafaxine (Effexor), duloxetine (Cymbalta), and desvenlafaxine (Pristiq), do what their name says: they block the reuptake of both serotonin and norepinephrine at the same time. By keeping both of these chemical messengers active in the synapse longer, SNRIs activate a broader set of downstream signals in the brain.⁴

In practice, SNRIs are often tried when an SSRI has not worked well enough, or when a person’s depression comes with significant fatigue or physical pain. Duloxetine, for example, has separate approvals for chronic pain conditions like fibromyalgia and diabetic nerve pain. The norepinephrine component is thought to contribute to those analgesic effects. Side effects overlap considerably with SSRIs (nausea, sexual dysfunction, insomnia), but SNRIs can also raise blood pressure at higher doses because norepinephrine plays a role in cardiovascular regulation.

Older Classes That Are Still in Use

Before SSRIs existed, the two main options were tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Both were discovered through clinical observation rather than rational drug design, and both turned out to work by boosting serotonin and norepinephrine, just through different mechanisms.

Tricyclics like amitriptyline, nortriptyline, and imipramine block the reuptake of serotonin and norepinephrine much like SNRIs do, but they also stick to a range of other receptor types they were never meant to hit. Specifically, they block histamine, acetylcholine, and alpha-1 adrenergic receptors, and those off-target actions produce side effects like weight gain, dry mouth, constipation, drowsiness, and dizziness.⁵ Tricyclics can also be dangerous in overdose because of their effects on cardiac rhythm, which is a major reason they lost their front-line status once SSRIs arrived. They are still prescribed, though, particularly for treatment-resistant depression, chronic pain, and certain anxiety disorders where their broader pharmacology can be an asset.

MAOIs work differently. Instead of blocking reuptake, they inhibit the enzyme monoamine oxidase, which normally breaks down serotonin, norepinephrine, and dopamine inside the nerve cell. By disabling this cleanup enzyme, MAOIs let those neurotransmitters build up.⁶ The catch is dietary: monoamine oxidase also breaks down tyramine, an amino acid found in aged cheeses, cured meats, and fermented foods. If someone on an MAOI eats too much tyramine, it can cause a dangerous spike in blood pressure. That dietary restriction, along with serious drug interactions, makes MAOIs a last-resort option for most prescribers. They remain valuable for certain people whose depression does not respond to anything else.

Atypical Antidepressants

Several antidepressants do not fit neatly into the SSRI, SNRI, TCA, or MAOI categories. The most well-known is bupropion (Wellbutrin), which works by inhibiting the reuptake of norepinephrine and dopamine without any meaningful serotonin activity.⁷ Because it skips serotonin entirely, bupropion avoids the sexual side effects and weight gain that many people experience on SSRIs and SNRIs. It is also approved for smoking cessation and sometimes prescribed off-label for attention difficulties. The main downside is that it can increase anxiety and, at high doses, slightly raises the risk of seizures.

Mirtazapine (Remeron) takes yet another approach, blocking certain norepinephrine and serotonin receptors to increase neurotransmitter release indirectly. It tends to be sedating and appetite-stimulating, which makes it useful for depressed patients who are losing sleep and weight but less ideal for those worried about gaining weight.

Multimodal Agents

A newer generation of antidepressants combines serotonin transporter blockade with direct activity at multiple serotonin receptor subtypes. Vortioxetine (Trintellix) is the clearest example. It blocks the serotonin transporter like an SSRI, but it also blocks several serotonin receptor types (5-HT3, 5-HT7, and 5-HT1D), partially activates 5-HT1B receptors, and fully activates 5-HT1A receptors.⁸ The idea is that fine-tuning serotonin signaling at the receptor level can improve outcomes beyond what simple reuptake blockade achieves. Some evidence suggests vortioxetine may have cognitive benefits that go beyond mood improvement, which has made it a popular choice for patients who report “brain fog” alongside depression.

Vilazodone (Viibryd) similarly combines serotonin reuptake inhibition with direct receptor agonism at the 5-HT1A receptor. Research has shown that vilazodone binds to the serotonin transporter in a physically different site than traditional SSRIs, which may account for its somewhat distinct clinical profile.⁹

Why Most Antidepressants Take Weeks to Work

One of the most frustrating aspects of starting an antidepressant is the delay. SSRIs begin blocking serotonin reuptake within hours, yet you may not feel meaningfully better for four to six weeks. This gap has puzzled researchers for decades, and the leading explanation involves the brain’s own feedback systems.

When serotonin levels first rise at the synapse, the neuron that released it detects the surge through sensors called autoreceptors (specifically 5-HT1A autoreceptors in the raphe nuclei). These sensors interpret the spike as “too much serotonin” and dial back the neuron’s firing rate, partially canceling out the drug’s effect. Over days to weeks of continued treatment, those autoreceptors gradually lose their sensitivity. Once that feedback brake weakens, serotonin neurons resume normal firing but now with the reuptake pump still blocked, so serotonin levels genuinely climb and stay elevated in key mood-regulating regions.¹⁰¹¹

There is also a deeper layer. Sustained antidepressant treatment gradually increases the production of brain-derived neurotrophic factor (BDNF), a protein that supports the growth and strengthening of neural connections. This slow buildup of BDNF is thought to help the brain rewire mood circuits over time, and it tracks closely with the timeline of clinical improvement.¹² Remission rates with standard monoamine-based antidepressants, despite this process, remain under about 60%, which has driven the search for faster-acting alternatives.¹³

Rapid-Acting Antidepressants

The game changed in 2000 when researchers showed that ketamine, a drug previously known mainly as an anesthetic and a party drug, could produce antidepressant effects within hours. Ketamine works on an entirely different brain system: instead of serotonin or norepinephrine, it blocks NMDA receptors in the glutamate system, the brain’s primary excitatory signaling network. That blockade triggers a cascade of events that ultimately strengthens synaptic connections, a form of rapid neural rewiring that outlasts the drug’s short presence in the body.¹⁴ This contrasts sharply with SSRIs, which need weeks of chronic use to slowly coax a similar kind of neural plasticity through BDNF.¹²

An FDA-approved nasal spray form, esketamine (Spravato), is now available for treatment-resistant depression, though it must be administered in a clinical setting because of sedation and dissociation risks. In network analyses comparing treatments for patients who have not responded to standard antidepressants, ketamine and NMDA-targeting agents showed response rates roughly three times higher than placebo.¹⁵

Another fast-acting approach targets a completely different mechanism: the GABA system. Zuranolone, approved for postpartum depression, mimics allopregnanolone, a naturally occurring brain steroid that enhances the activity of GABA-A receptors. GABA is the brain’s main inhibitory neurotransmitter, and its receptor is the same one targeted by benzodiazepines, though zuranolone binds at a different spot. Clinical trials found zuranolone effective compared to placebo for postpartum depression, with a treatment course lasting just 14 days.¹⁶

Discontinuation Syndrome

Stopping an antidepressant too quickly can trigger a cluster of symptoms that is sometimes confused with a relapse of depression itself. Common complaints include dizziness, nausea, irritability, “brain zaps” (brief electric-shock-like sensations), insomnia, and flu-like body aches. This happens because the brain has adapted to the drug’s presence, and a sudden drop in serotonin availability when the drug is withdrawn leaves multiple neurotransmitter systems temporarily out of balance. The serotonin, norepinephrine, and cholinergic systems all appear to play a role in the symptoms.¹⁷

Drugs with shorter half-lives, like paroxetine and venlafaxine, tend to produce worse discontinuation symptoms because their blood levels drop faster. Fluoxetine, with its very long half-life, naturally tapers itself and is less likely to cause problems. The standard clinical approach is to reduce the dose gradually over weeks or months, and in stubborn cases, temporarily switching to fluoxetine before tapering can smooth the transition.

Serotonin Syndrome

Serotonin syndrome is a rare but potentially dangerous condition caused by too much serotonin activity. It exists on a spectrum from mild (tremor, diarrhea, agitation) to life-threatening (high fever, seizures, muscle rigidity). The condition is characterized by neuromuscular abnormalities, autonomic hyperactivity, and mental state changes, and it typically requires two or more serotonin-boosting drugs taken simultaneously, though it can occasionally occur with a single drug in susceptible individuals.¹⁸

The most dangerous combination is an MAOI with another serotonin-boosting drug, which can precipitate the most severe form and occasionally cause death.¹⁸ This is why switching from an MAOI to an SSRI (or vice versa) requires a washout period of at least two weeks, and why prescribers are cautious about combining any two drugs that raise serotonin through different mechanisms. Even certain migraine medications (triptans), the cough suppressant dextromethorphan, and the herbal supplement St. John’s wort carry serotonin-related interaction risks.

When Standard Treatments Fall Short

Roughly a third of people with depression do not respond adequately to their first antidepressant, and a significant minority do not respond to two or more trials, at which point their condition is classified as treatment-resistant. A systematic review and network analysis of treatments for this group found that several interventions outperformed placebo. Electroconvulsive therapy (ECT) showed the strongest effect, with odds of response roughly 13 times higher than placebo. NMDA-targeting agents like ketamine came in with about three times the odds, and certain add-on antipsychotics like aripiprazole also showed benefit.¹⁵

Augmentation strategies, where a second medication is added to an antidepressant rather than replacing it, are a common approach. Atypical antipsychotics (aripiprazole, quetiapine, olanzapine) are the most studied augmentation agents, though lithium and thyroid hormone have been used for decades in this role. Transcranial magnetic stimulation (TMS), a non-drug option that uses magnetic pulses to stimulate specific brain regions, has also shown promise in the treatment-resistant population.

Pharmacogenomics and Why the Same Drug Works Differently in Different People

One reason antidepressant prescribing still involves trial and error is that people metabolize these drugs at very different rates. The liver enzymes responsible for breaking down most antidepressants, particularly the cytochrome P450 family (CYP2D6 and CYP2C19 are the big ones for this class), come in many genetic variants. Someone who metabolizes a drug ultra-rapidly may never reach a therapeutic blood level at standard doses, while a poor metabolizer may accumulate the drug and experience exaggerated side effects. Research has found that these genetic differences can influence which specific antidepressant is most likely to produce remission for a given individual.¹⁹

Commercial pharmacogenomic tests are now available and sometimes covered by insurance, but the field is still maturing. Current tests can flag extreme metabolizer phenotypes that might cause problems with certain drugs, which is useful. What they cannot yet do reliably is tell you which antidepressant will work best for your specific depression. The genetic picture of drug metabolism is clearer than the genetic picture of treatment response, and most prescribers treat test results as one piece of information rather than a definitive guide.

The FDA Black Box Warning in Children and Adolescents

Since 2003, the FDA has warned that antidepressants may be associated with suicidal thoughts and behaviors in young people. A formal black box warning, the most serious label warning the agency issues, was added in 2005 for patients under 18.²⁰ The warning was later extended to young adults up to age 25.

The story behind this warning is complicated. The original signal came from clinical trial data showing a small increase in suicidal thinking (not completed suicides) in young patients on antidepressants compared to placebo. The warning achieved its goal of increasing monitoring, but it also had unintended consequences: prescriptions for adolescents dropped, while youth suicide rates in some populations actually rose. Whether the drop in prescribing contributed to those rising rates is debated, but the pattern made clear that untreated depression carries its own serious risks. Current guidance generally supports using antidepressants in young people when clinically indicated, with close follow-up especially in the first weeks of treatment.

The Placebo Response in Depression

Depression trials consistently show large placebo responses, sometimes reaching 30 to 40 percent improvement, which is one reason it can be hard to demonstrate that a new drug works. This is not imaginary healing. Brain imaging research has shown that placebo treatment in depression activates the brain’s own opioid system. In one study, patients given an active placebo (a pill they believed was a real antidepressant) showed increased release of endogenous opioids in brain regions tied to emotion and stress regulation, including the nucleus accumbens and anterior cingulate cortex. The degree of that opioid release predicted how well the patient later responded to actual antidepressant medication, accounting for about 43 percent of the variance in symptom improvement.²¹

The practical takeaway is that expectancy and the therapeutic relationship are not trivial add-ons to drug treatment; they engage real neurochemical pathways that overlap with the drug’s own target systems. This is one reason psychotherapy combined with medication tends to outperform medication alone, and why believing a treatment will help is not wishful thinking but an active ingredient in recovery.

How Antidepressants Interact with the Gut

About 90 percent of the body’s serotonin is produced in the gut, not the brain, and a growing body of research shows that antidepressants do not only affect the central nervous system. They also alter the composition of intestinal bacteria. Studies in animal models have demonstrated that several types of antidepressants change gut microbiota composition, and those shifts may be connected to treatment outcomes.²² The relationship runs both directions: the abundance and makeup of gut bacteria may also influence how well an antidepressant works for a given person.²³

This research is still early-stage, and nobody should be adjusting their antidepressant based on a stool test. But it helps explain why gastrointestinal side effects are so common with serotonin-targeting drugs, and it opens up the possibility that future treatment strategies could involve optimizing gut health alongside standard pharmacotherapy. Some researchers have speculated that the variability in antidepressant response from person to person could partly trace back to individual differences in gut microbial composition, though proving that will require much larger human studies than currently exist.

1
PubMed Central. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
2
PubMed Central. Structural basis for recognition of diverse antidepressants by the human serotonin transporter
3
PubMed. Antidepressant and tolerance: Determinants and management of major side effects
4
PubMed Central. New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
5
PubMed. Mechanism of action of antidepressant medications
6
PubMed Central. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
7
PubMed Central. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
8
PubMed. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data
9
Nature Communications. The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter
10
PubMed Central. Delayed Antidepressant Efficacy and the Desensitization Hypothesis
11
PubMed. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects
12
PubMed Central. Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants
13
Europe PMC. A brief history of the development of antidepressant drugs: from monoamines to glutamate
14
Neuropsychopharmacology. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
15
Neuropsychopharmacology. Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials
16
PubMed Central. Zuranolone for the Treatment of Postpartum Depression
17
PubMed Central. Physiologic mechanisms underlying the antidepressant discontinuation syndrome
18
PubMed Central. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions
19
Neuropsychopharmacology. Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward
20
PubMed. Intended And Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review
21
JAMA Psychiatry. Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression
22
Translational Psychiatry. Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior
23
Neurotherapeutics. Current Perspectives Interactions Between Antidepressants and Intestinal Microbiota